Iwamoto, Kunihiro http://orcid.org/0000-0003-3868-3372
Iwata, Mari
Kambe, Daiji
Imadera, Yumiko
Tachibana, Naoki
Kajiyama, Yu
Ando, Masahiko
Ozaki, Norio
Funding for this research was provided by:
Research on Regulatory Science of Pharmaceuticals and Medical Devices from the Japan Agency for Medical Research and Development (JP21mk0101137h0003)
Ministry of Education, Culture, Sports, Science and Technology of Japan
Ministry of Health, Labour and Welfare
Grant-in-Aid from the “Center of Innovation for Personalized and Diverse Society” carried out under the Center of Innovation Program from the Japan Science and Technology Agency
Article History
Received: 16 September 2021
Accepted: 24 January 2022
First Online: 1 February 2022
Declarations
:
: KI has received speakers’ honoraria from Eisai, Kyowa, Meiji Seika Pharma, Otsuka, Sumitomo Dainippon, Taisho, Takeda, and Towa. MI has no conflicts of interest to declare. DK, YI, KN, and YK are employees of Taisho Pharmaceutical Co., Ltd., Japan. MA has received subsidies from Kyowa Kirin. NO has received research support or speakers’ honoraria from, or has served as a consultant to, Sumitomo Dainippon, Eisai, Otsuka, KAITEKI, Mitsubishi Tanabe, Shionogi, Eli Lilly, Mochida, DAIICHI SANKYO, Nihon Medi-Physics, Takeda, Meiji Seika Pharma, EA Pharma, Pfizer, MSD, Lundbeck Japan, Taisho Pharma, Janssen, UCB, Shionogi, Nihon Medi-Physics, Tsumura, Novartis, and Astellas.